GLP-1 manufacturers bear liability for not warning US patients about NAION

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

CDC and HHS leadership, research integrity, bioethics, regulatory appointments, e-cigarette regulation, and global health funding.

Monitoring and prevention of adverse effects from medications.

Common and serious adverse reactions linked to GLP-1 drugs, including gastrointestinal symptoms, gallbladder issues, pancreatitis concerns, muscle loss, and long-term safety questions.